Immunotherapy for colorectal cancer

Expert Review of Anticancer Therapy

Volumn 3, Issue 1, 2003, Pages 63-78

  Midgley, Rachel S ^a   Kerr, David J ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antibody; CEA; Colorectal cancer; Cytotoxic T cell; Immunotherapy; Vaccine

Indexed keywords

105AD7; ALPHA INTERFERON; ALVAC; ANTIIDIOTYPIC ANTIBODY; BCG VACCINE; BUTYRIC ACID; CANCER VACCINE; CARCINOEMBRYONIC ANTIBODY; CEAVAC; CYCLOPHOSPHAMIDE; EDRECOLOMAB; EPITOPE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; LEVAMISOLE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; MUCIN 1; PEPTIDE; PHOSPHORYL LIPID A; POLYNUCLEOTIDE; RAS PROTEIN; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2; THERATOPE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINIA VACCINE; VIRUS VACCINE;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; FEVER; HUMAN; IMMUNOTHERAPY; MALAISE; MONOTHERAPY; NAUSEA; NONHUMAN; REVIEW; RIGOR; THROMBOCYTOPENIA; ULCER; VOMITING;

EID: 0037320737     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.1.63     Document Type: Review

References (77)

1. Suzuki A, Masuda A, Nagata H et al. Mature dendritic cells make clusters with T-cells in the invasive margin of colorectal carcinoma. J Pathol. 196(1), 37-43 (2002).
2. Smith ME, Marsh SG, Bodmer JG et al. Loss of HLA-A, B, C allele products and lymphocyte function associated antigens in colorectal neoplasia. Proc. Natl. Acad. Sci USA 89, 5557-5561 (1989).
3. Lopez-Neust MA, Esteban F, Ferron A et al. HLA class I gene expression on human primary tumors and autologous metastases: demonstration of selective loss of HLA antigens on colorectal, gastric and laryngeal carcinomas. Br. J. Cancer 59(2), 221-226 (1989).
4. Bicknell DC, Kaklamanis L, Hampson R, Bodmer WF, Kerran P. Selection for β2 microglobulin mutation in mis-match repair-defective colorectal carcinomas. Curr. Biol. 6(12), 1695-1697 (1996).
5. Kaklaminis L, Townsend A, Doussis-Anagnostopoulo IA. Loss of major histocompatability complMex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am. J. Pathol. 145(3), 505-509 (1994).
6. Gimmi CD, Morrison BW, Mainprice BA et al. Breast cancer-associated antigen DF3/MUC1, induces apoptosis of activated human T cells. Nature Med. 2, 367-370 (1996).
7. Younes M, Schwartz MR, Finnie D, Younes A. Overexpression of fas-ligand (FasL) during malignant transformation in the large bowel and in Barrett's metaplasia of the oesophagus. Human Pathol. 30(11), 1309-1313 (1999).
8. Nakagomi H, Petersson M, Magnusson I et al. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53, 5610-5612 (1993).
9. Gastl GA, Abrams JS, Nanus DM et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int. J. Cancer 55, 96-101 (1993).
10. Kanai T, Watanabe M, Hayashi A et al. Regulatory effect of interleukin-4 and interleukin-13 on colon cancer cell adhesion. Br. J. Cancer 82(10), 1717-1723 (2000).
11. Brivio F, Lissoni P, Pergo MS, Lissoni A, Fumagilli L. Abrogation of surgery-induced. IL6 hypersecretion by presurgical immunotherapy with IL-2 and its importance in the prevention of postoperative complications. J. Biol. Regul. Homeost. Agents 15(4), 370-374 (2001).
12. Heriot AG, Marriott JB, Cookson S, Kumar D, Dalgleish AG. Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection. Br. J. Cancer 82(5), 1009-1012 (2000).
13. Falk RE, MacGregor AB, Landi S et al. Immunostimulation with intraperitoneally administered Bacille-Calmette Guerin for advanced malignant tumors of the GI tract. Surg. Gynaecol. Obstet. 142, 363-368 (1976).
14. Mavligit GM, Gutterman JU, Malahy MA et al. Adjuvant immunotherapy and chemotherapy in colorectal cancer (Dukes' class C), prolongation of disease-free interval and survival. Cancer 40(5 Suppl.), 2726-2730 (1977).
15. Gastro-intestinal Tumor Study Group. Adjuvant therapy of colon cancer-results of a prospectively randomized trial. N Engl. J. Med. 310(2), 737-743 (1984).
16. Moertel CG, Fleming TR, MacDonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med. 322(6), 352-358 (1990).
17. Quasar Collaborative Group. Comparison of fluorouracil with the addition of levamisole, higher dose folinic acid, or both as adjuvant chemotherapy for colorectal cancer, a randomized trial. Lancet 355, 1588-1596 (2000).
18. Rosenberg SA, Lope MT, Yang JC et al. Experience with the use of high dose interleukin2 in the treatment of 652 cancer patients. Ann. Surg. 210, 474-485 (1989).
19. Brivio F, Lissini P, Alden G et al. Pre-operative IL-2 subcutaneous immunotherapy may prolong survival time in advanced colorectal cancer patients. Oncology 53, 263-268 (1996).
20. Douillard JY, Bennouna J, Vavasseur F et al. Phase I trial of interleukin2 and high dose arginine butyrate in metastatic colorectal cancer. Cancer Immunol. Immunother. 49, 56-61 (2000).
21. Seymour MT, Stevin HL, Kerr DJ et al. Randomized trial assessing the addition of interferon α-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J. Clin. Oncol. 14(8), 2280-2288 (1996).
22. Southern Italy Oncology Group. 5-fluorouracil and levofolinic acid with or without recombinant interferonα2b in patients with advanced colorectal carcinoma. Cancer 85(3), 535-545 (1999).
23. Hausminger H, Moser R, Samonigg H et al. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferonα2c in patients with advanced colorectal carcinoma, final results of a randomized Phase III study. Eur. J. Cancer 35(3), 380-385 (1999).
24. Fountzilas G, Zisiadis A, Pafni U et al. Fluorouracil and leucovorin with or without interferonα2a as adjuvant treatment, in patients with high risk colon cancer. Oncology 58, 227-236 (2000).
25. Benchimol S, Fuks A, Jothy S et al. Carcino-embryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 57, 327-334 (1989).
26. Screaton R, Penn L, Stanners C. Carcino-embryonic antigen, a human tumor marker, cooperates with Myc and bcl-2 in cellular transformation. J. Cell Biol. 137, 939-952 (1997).
27. Taheri M, Saragovi U, Fuks A et al. Self-recognition in the Ig superfamily, identification of precise subdomains in carcino-embryonic antigen required for intercellular adhesion. J. Biol. Chem. 275, 26935-26943 (2000).
28. Ordonez C, Screaton RA, Ilantzis C et al. Human carcino-embryonic antigen functions as a general inhibitor of anoikis. Cancer Res. 60, 3419-3424 (2000).
29. Tsang K, Zaremba S, Nieroda CA et al. Generation of human cytotoxic T cells specific for human carcino-embryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl Cancer Inst. 87, 982-990 (1995).
30. Nukaya I, Yasumoto M, Iwasaki T et al. Identification of HLA-A24 epitope peptides of carcino-embryonic antien which induce tumor-reactive cytotoxic T lymphocytes. Int. J. Cancer 80(1), 92-97 (1999).
31. Kawashimi I, Tsai V, Southwood S et al. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcino-embryonic antigen and her2/neu by priming in vitro immunization with peptide-pulsed dendritic cells. Cancer Res. 59(2), 431-435 (1999).
32. Huarte E, Sarobe P, Lasarte JJ et al. Identification of HLA-B27-restricted cytotoxic T lymphocyte epitope from carcino-embryonic antigen. Int. J. Cancer 97, 58-63 (2002).
33. Riethmuller G, Holtz E, Schliomock G et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven year putcome of a multi-center randomized trial. J. Clin. Oncol. 16, 1788-1794 (1989).
34. Punt CJ, Nagy A, Douillard JY et al. Edrocolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomized study. Lancet 360, 671-677 (2002).
35. Behr TM, Liersch T, Greiner-Bechert L et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 94(Suppl. 4), 1373-1381 (2002).
36. Napier MP, Sharma SK, Springer CJ et al. Antibody-directed prodrug therapy; efficacy and mechanism of action in colorectal carcinoma. Clin. Cancer Res. 6, 765-772 (2000).
37. Foon K, John WJ, Chakraborty M et al. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotypic monoclonal antibody vaccine that mimics the carcino-embryonic antigen. Clin. Cancer Res. 3, 1267-1276 (1997).
38. Foon K, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotypic monoclonal antibody vaccine that mimics the carcino-embryonic antigen. J. Clin. Oncol. 17, 2889-2895 (1999).
39. Denton GWL, Durrant LG, Hardcastle JD et al. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int. J. Cancer 57, 10-14 (1994).
40. Maxwell-Armstrong CA, Durrant LG, Robins RA et al. Increased activation of lymphocytes infiltrating primary colorectal cancers following immunization with the anti-idiotypic monoclonal antibody 105AD7. Gut 45(4), 593-598 (1999).
41. Amin S, Robins A, Maxwell-Armstrong CA et al. Vaccine-induced apoptosis: a novel clinical trial end-point? Cancer Res. 60(12), 3132-3136 (2000).
42. Durrant LG, Maxwell-Armstrong C, Buckley D et al. A neo-adjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin. Cancer Res. 6(2), 422-430 (2000).
43. Maxwell-Armstrong CA, Durrant LG, Buckley TJ et al. Randomized double-blind phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Br. J. Cancer 84(11), 1443-1446 (2001).
44. Kim A, Bresler H, Martin EW et al. Cellular immunotherapy for patients with metastatic colorectal carcinoma using lymph node lymphocytes localised in vivo by radiolabelled monoclonal antibody. Cancer 86(1), 22-30 (1999).
45. Becker C, Pohla H, Frankenberger B et al. Adoptive tumor therapy with T lymphocytes enriched through an IFN-γ capture assay. Nature Med. 7(10), 1159-1162 (2001).
46. Tsang KY, Zhu M, Nieroda CA et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcino-embryonic antigen. Clin. Cancer Res. 3(12), 2439-2449 (1997).
47. Hoover HC Jr, Brandhorst JS, Peters LC et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow-up of a Phase III prospectively randomized trial. J. Clin. Oncol. 11, 390-399 (1993).
48. Harris JE, Rajan L, Hoover HC et al. Adjuvant ASI for Stage II and Stage III colon cancer with autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study, E5283. J. Clin. Oncol. 18(1), 148-157 (2000).
49. Vermorken JB, Claesen AME, van Tinteren H et al. Active specific immunotherapy for Stage II and Stage III human colon cancer: a randomized trial. Lancet 353, 345-350 (1999).
50. Sobol RE, Shawler DC, Carson C. Interleukin2 gene therapy of colorectal carcinomas with autologous irradiated tumor cells and genetically-engineered fibroblasts: a phase I study. Clin. Cancer Res. 5(9), 2359-2365 (1999).
51. Goydos JS, Elder E, Whiteside TL, Finn OJ, Lotze MT. A Phase I trial of synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinomas. J. Surg. Res. 63, 298-304 (1996).
52. Reddish MA, MacClean GP, Poppema S et al. Pre-immunotherapy serum CA27.29 (MUC1) mucin level and CD69+ lymphocytes correlate with effects of Theratope® sialyl-Tn-KLH cancer vaccine in active specific immunotherapy. Cancer Immunol. Immunother. 42, 303-309 (1996).
53. Tempero M, MacLean GD, Palmer M, Meikle A, Kehoe M, Longenecker M. Theratope vaccine in metastatic cancer: immunogeniciiy and survival in a dose range study. Proc. Soc. Clin. Oncol. 20, 252a (2001).
54. Khleif SN, Abrams SI, Hamilton JM et al. A Phase I trial with peptides reflecting ras oncogene mutations of solid tumors. J. Immunother. 22(2), 155-165 (1999).
55. Alters SE, Gadea JR, Sorich M et al. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with a restricted TCR repertoire. J. Immunother. 21(1), 17-26 (1998).
56. Morse MA, Deng Y, Coleman D et al. A Phase I study of active immunotherapy with carcino-embryonic antigen peptide (CAP-1)-pulsed autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcino-embryonic antigen. Clin. Cancer Res. 5(6), 1331-1338 (1999).
57. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand-expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. USA 98, 8809-8814 (2001).
58. Sadanaga N, Nagashima H, Mashino K et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7(8), 2277-2284 (2001).
59. Chang AE, Redman BG, Whitfield JR et al. A Phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin. Cancer Res. 8, 1021-1032 (2002).
60. Tsang KY, Zhu MZ, Even J, Gulley J, Arlen P, Schlom J. The infection of human dendritic cells with recombinant Avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Cancer Res. 61, 7568-7576 (2001).
61. Hodge J, McLaughlin JP, Kantor JA et al. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T cell immunity and anti-tumor responses. Vaccine 15, 759-768 (1997).
62. Conry R, Allen KO, Lee S et al. Human autoantibodies to carcino-embryonic antigen (CEA) induced by a vaccinia-CEA vaccine. Clin. Cancer Res. 6, 34-41 (2000).
63. Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcino-embryonic antigen. J. Clin. Oncol. 17(1), 332-337 (1999).
64. Zhu MZ, Marshall J, Cole D, Schlom J, Tsang KY. Specific cytolytic T cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6(1), 24-33 (2000).
65. Marshall JL, Hoyer RJ, Toomey MA et al. Phase I study in advanced cancer patients of a diversified prime and boost vaccination protocol using recombinant vaccinia virus and recombinant non-replicating Avipox virus to elicit anti-carcinoembryonic antigen immune responses. J. Clin. Oncol. 18, 3964-3974 (2000).
66. Von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recominant avipox vaccine containing both carcino-embryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6, 2219-2228 (2000).
67. Horig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypox virus (ALVAC) vaccine expressing human crcino-embryonic antigen and the B7.1 costimulatory molecule. Cancer Immunol. Immunother. 49, 504-514 (2000).
68. von Mehren M, Arlen P, Gulley J et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin. Cancer Res. 7, 1181-1191 (2001).
69. Kass E, Parker J, Schlom J, Greiner JW. Comparative studies of the effects of recombinant GMCSF and GMCSF administered via a poxvirus to enhance the concentration of antigen-presenting cells in regional lymph nodes. Cytokine 12(7), 960-971 (2000).
70. Kass E, Panicali DL, Mazzara. G, Schlom J, Greiner JW. Granulocyte/ macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes wiith antigen-presenting cells and acts as a immunoadjuvant. Cancer Res. 61(1), 206-214 (2001).
71. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
72. Reynolds SR, Oratz R, Shapiro RL et al. Stimulation of CD8+ T cell responses to MAGE3 and Melan A/ MART-1 by immunization to a polyvalent melanoma vaccine. Int. J. Cancer 72, 972-976 (1997).
73. Lee KH, Wang E, Nielsen MB, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163, 6292-6300 (1999).
74. Van der Berg SH, Menon AG, Redeker A et al. Induction of p53 specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. 8 (5), 1019-1027(2002).
75. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a β-human chorionic gonadotrophin peptide vaccine in patients with metastatic colorectal cancer: Antibody response is associated with improved survival. Clin. Cancer Res. 8(7), 2044-2051 (2002).
76. Miyaga Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. 7(12), 3950-3962 (2001).
77. Perez SA, Sotiropoulou PA, Sotirodou NN et al. Her2/neu-derived peptide 884-899 is expressed by human breast, colorectal, and pancreatic adenocarcinomas and is recognized by in vitro-induced specific CD4+ T cell clones. Cancer Immunol. Immunother. 50, 615-624 (2002).